Efficacy of pertussis components in an acellular vaccine, as assessed in a murine model of respiratory infection and a murine intracerebral challenge model.
The efficacy of 10 pertussis vaccines prepared from various concentrations of pertussis toxin (PT) and filamentous hemagglutinin (FHA) was investigated in a murine model of respiratory infection (aerosol challenge model) and a murine intracerebral (ic) challenge model. PT was necessary as a vaccine component for protection against an ic challenge with Bordetella pertussis. FHA appeared to play an important role as a vaccine component in protection against an aerosol challenge with B. pertussis. Vaccines containing a small amount of FHA with a large amount of PT (FHA:PT=1:11 or 2:10, w/w) were strongly protective in both the aerosol challenge and the ic challenge models. Ratios of FHA:PT of 1:11 or 2:10 (w/w) might be suitable for future formulations.
Watanabe
Mineo
M
Research Center for Biologicals, The Kitasato Institute, 6-111 Arai, Kitamoto, 364-0026, Saitama, Japan.
Komatsu
Eiji
E
Abe
Katsuyo
K
Iyama
Shigeharu
S
Sato
Takaaki
T
Nagai
Masaaki
M
D018829:Adhesins, Bacterial / Q000008:administration & dosage* / Q000276:immunology; D000336:Aerosols; D000818:Animals; D001921:Brain / Q000382:microbiology*; D004195:Disease Models, Animal; D004306:Dose-Response Relationship, Immunologic; D005260:Female; D006388:Hemagglutinins / Q000008:administration & dosage* / Q000276:immunology; D008168:Lung / Q000382:microbiology*; D051379:Mice; D037342:Pertussis Toxin; D010567:Pertussis Vaccine / Q000008:administration & dosage* / Q000276:immunology; D013997:Time Factors; D022282:Vaccines, Acellular / Q000008:administration & dosage; D010566:Virulence Factors, Bordetella / Q000008:administration & dosage* / Q000276:immunology
D018829:Adhesins, Bacterial; D000336:Aerosols; D006388:Hemagglutinins; D010567:Pertussis Vaccine; D022282:Vaccines, Acellular; D010566:Virulence Factors, Bordetella; C065273:filamentous hemagglutinin adhesin, Bordetella pertussis; D037342:Pertussis Toxin